1. Home
  2. TORO vs KRRO Comparison

TORO vs KRRO Comparison

Compare TORO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$4.99

Market Cap

174.5M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$10.60

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
KRRO
Founded
2022
2014
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.5M
187.9M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
TORO
KRRO
Price
$4.99
$10.60
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
24.4K
188.0K
Earning Date
04-15-2026
05-13-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$2.64
$5.20
52 Week High
$8.50
$55.89

Technical Indicators

Market Signals
Indicator
TORO
KRRO
Relative Strength Index (RSI) 51.07 34.70
Support Level $4.87 $9.76
Resistance Level $5.25 $14.53
Average True Range (ATR) 0.17 0.98
MACD 0.02 -0.37
Stochastic Oscillator 56.67 7.37

Price Performance

Historical Comparison
TORO
KRRO

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: